Please assess the completion status of the following clinical trial:

Trial Title: Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Known Diabetes mellitus \> 6 months~* Increased Nt-proBNP above 125pg/ml~* Given informed consent~Exclusion Criteria:~* Disease other than diabetes, with a life expectancy below 1 year~* patients who suffer from chronic infection or malignant disease~* Women in childbearing age without contraceptive~* History of cardiac disease~* systemic cortisone treatment~* patients who are on chronic or acute hemodialysis, ultra filtration or peritoneal dialysis

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
- 2 (Type: PLACEBO_COMPARATOR): Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).